Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

25.87 

0.26 1.0%

as of Mar 20 '23

52 Week Range:

24.63 265.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Sep '14 Jan '15 Sep '15 Jan '16 Sep '16 Jan '17 Sep '17 Sep '18 Sep '19 Sep '20 Sep '21
Equity (BVPS) 22.08
30.59
33.57
46.86
68.42
72.65
70.54
73.14
growth rate 17.7% 4.8% 18.2% 46.0% 6.2% -2.9% 3.7%
Earnings BIT 1,632.00
1,793.00
2,158.00
2,243.00
2,772.00
2,944.00
2,520.00
3,369.00
growth rate 4.8% 9.7% 2.0% 23.6% 6.2% -14.4% 33.7%
Avg.PE 29.05
15.40
54.71
354.40
57.62
60.75
60.75
growth rate -47.0% 255.3% 547.8% -83.7% 5.4% 0.0%
ROA 9.64
3.54
3.72
3.25
0.35
2.05
1.45
3.71
growth rate -39.4% 2.5% -6.5% -89.2% 485.7% -29.3% 155.9%
ROE 23.48
11.38
13.19
10.01
0.94
5.14
3.42
8.44
growth rate -30.4% 7.7% -12.9% -90.6% 446.8% -33.5% 146.8%
ROIC 13.91
7.10
6.69
5.09
1.69
3.71
2.99
5.86
growth rate -28.6% -2.9% -12.8% -66.8% 119.5% -19.4% 96.0%
Cur. Ratio 2.74
1.38
1.45
5.58
1.02
1.18
1.54
1.33
growth rate -29.0% 2.5% 96.2% -81.7% 15.7% 30.5% -13.6%
Quick Ratio 1.76
0.72
0.80
4.78
0.48
0.51
0.90
0.72
growth rate -36.0% 5.4% 144.4% -90.0% 6.3% 76.5% -20.0%
Leverage 2.46
3.74
3.35
2.91
2.57
2.46
2.27
2.28
growth rate 23.3% -5.4% -6.8% -11.7% -4.3% -7.7% 0.4%
Balance Sheet Sep '14 Jan '15 Sep '15 Jan '16 Sep '16 Jan '17 Sep '17 Sep '18 Sep '19 Sep '20 Sep '21
Acct.Receivable 1,192.00
1,693.00
1,957.00
1,744.00
2,319.00
2,345.00
2,398.00
2,497.00
growth rate 19.2% 7.5% -5.6% 33.0% 1.1% 2.3% 4.1%
Acct.Payable 401.00
631.00
665.00
797.00
1,106.00
1,092.00
1,355.00
1,793.00
growth rate 25.4% 2.7% 9.5% 38.8% -1.3% 24.1% 32.3%
Cur.Assets 6,130.00
5,659.00
6,365.00
18,633.00
7,411.00
6,664.00
8,969.00
8,838.00
growth rate -3.9% 6.1% 71.1% -60.2% -10.1% 34.6% -1.5%
Total Assets 12,447.00
26,478.00
25,586.00
37,734.00
53,904.00
51,765.00
54,012.00
53,866.00
growth rate 45.9% -1.7% 21.4% 42.9% -4.0% 4.3% -0.3%
Cash 1,861.00
1,424.00
1,541.00
14,179.00
1,140.00
536.00
2,825.00
2,283.00
growth rate -12.5% 4.0% 203.3% -92.0% -53.0% 427.1% -19.2%
Inventory 1,495.00
1,959.00
1,719.00
1,818.00
2,451.00
2,579.00
2,743.00
2,866.00
growth rate 14.5% -6.3% 2.8% 34.8% 5.2% 6.4% 4.5%
Cur.Liabilities 2,235.00
4,381.00
4,400.00
3,342.00
7,216.00
5,655.00
5,836.00
6,626.00
growth rate 40.0% 0.2% -12.9% 115.9% -21.6% 3.2% 13.5%
Liabilities 7,394.00
19,314.00
17,953.00
24,786.00
32,910.00
30,684.00
30,247.00
30,189.00
growth rate 61.6% -3.6% 17.5% 32.8% -6.8% -1.4% -0.2%
LT Debt 3,768.00
11,370.00
10,550.00
18,667.00
18,894.00
18,081.00
17,224.00
17,110.00
growth rate 73.7% -3.7% 33.0% 1.2% -4.3% -4.7% -0.7%
Equity 5,053.00
7,164.00
7,633.00
12,946.00
20,992.00
21,079.00
23,763.00
23,675.00
growth rate 19.1% 3.2% 30.2% 62.2% 0.4% 12.7% -0.4%
Common Shares 198.00
208.00
218.00
224.00
347.00
347.00
365.00
365.00
growth rate 2.5% 2.4% 1.4% 54.9% 0.0% 5.2% 0.0%
Cash Flow Statement Sep '14 Jan '15 Sep '15 Jan '16 Sep '16 Jan '17 Sep '17 Sep '18 Sep '19 Sep '20 Sep '21
Capital Expenditures 592.00
596.00
693.00
727.00
895.00
957.00
810.00
1,231.00
growth rate 0.3% 7.8% 2.4% 23.1% 6.9% -15.4% 52.0%
Cash Dividends 421.00
485.00
562.00
677.00
927.00
984.00
1,026.00
1,048.00
growth rate 7.3% 7.7% 9.8% 36.9% 6.2% 4.3% 2.1%
Cash From OA 1,746.00
1,730.00
2,559.00
2,550.00
2,865.00
3,330.00
3,539.00
4,647.00
growth rate -0.5% 21.6% -0.2% 12.4% 16.2% 6.3% 31.3%
FCF per Share 5.16
3.96
7.75
5.20
6.22
7.84
7.58
12.34
growth rate -12.4% 39.9% -18.1% 19.6% 26.1% -3.3% 62.8%
Sale Purchase of Stock 4,827.00
4,827.00
4,827.00
4,827.00
growth rate 0.0% 0.0% 0.0%
FCF 1,091.00
-123.60
1,096.00
-139.50
1,841.00
-16.20
1,823.00
1,970.00
2,371.00
2,729.00
3,416.00
growth rate -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% 8.1% 20.4% 15.1% 25.2%
Income Statement Sep '14 Jan '15 Sep '15 Jan '16 Sep '16 Jan '17 Sep '17 Sep '18 Sep '19 Sep '20 Sep '21
Sales 8,446.00
10,282.00
12,483.00
12,093.00
15,983.00
17,290.00
17,117.00
20,248.00
growth rate 10.3% 10.2% -1.6% 32.2% 8.2% -1.0% 18.3%
Op.Income 1,632.00
1,793.00
2,158.00
2,243.00
2,772.00
2,944.00
2,520.00
3,369.00
growth rate 4.8% 9.7% 2.0% 23.6% 6.2% -14.4% 33.7%
IBT 1,522.00
739.00
1,073.00
976.00
1,173.00
1,176.00
985.00
2,242.00
growth rate -30.3% 20.5% -4.6% 20.2% 0.3% -16.2% 127.6%
Net Income 1,185.00
695.00
976.00
1,100.00
311.00
1,233.00
874.00
2,092.00
growth rate -23.4% 18.5% 6.2% -71.7% 296.5% -29.1% 139.4%
EPS 5.99
3.35
4.49
4.60
0.60
3.94
2.71
6.85
growth rate -25.2% 15.8% 1.2% -87.0% 556.7% -31.2% 152.8%
Gross Profit 4,301.00
4,988.00
5,991.00
5,965.00
7,805.00
8,288.00
7,919.00
9,576.00
growth rate 7.7% 9.6% -0.2% 30.9% 6.2% -4.5% 20.9%
R&D 524.00
632.00
828.00
770.00
1,004.00
1,032.00
1,096.00
1,339.00
growth rate 9.8% 14.5% -3.6% 30.4% 2.8% 6.2% 22.2%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 579.00
709.00
920.00
803.00
633.00
growth rate 22.5% 29.8% -12.7% -21.2%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 2,078.00
2,497.00
2,177.00
2,303.00
2,218.00
growth rate 20.2% -12.8% 5.8% -3.7%
Acct.Payable 1,793.00
growth rate
Cur.Assets 9,538.00
8,838.00
8,307.00
10,152.00
9,547.00
growth rate -7.3% -6.0% 22.2% -6.0%
Total Assets 54,333.00
53,866.00
53,363.00
54,786.00
53,199.00
growth rate -0.9% -0.9% 2.7% -2.9%
Cash 3,153.00
2,283.00
1,903.00
3,147.00
2,558.00
growth rate -27.6% -16.6% 65.4% -18.7%
Inventory 2,946.00
2,866.00
3,035.00
3,258.00
3,163.00
growth rate -2.7% 5.9% 7.4% -2.9%
Cur.Liabilities 7,749.00
6,626.00
6,735.00
6,657.00
7,080.00
growth rate -14.5% 1.7% -1.2% 6.4%
Liabilities 30,198.00
30,189.00
29,203.00
30,261.00
27,706.00
growth rate 0.0% -3.3% 3.6% -8.4%
LT Debt 15,700.00
17,110.00
16,360.00
17,584.00
14,683.00
growth rate 9.0% -4.4% 7.5% -16.5%
Equity 24,133.00
23,675.00
24,158.00
24,523.00
25,491.00
growth rate -1.9% 2.0% 1.5% 4.0%
Common Shares 365.00
365.00
365.00
365.00
365.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 267.00
465.00
188.00
227.00
growth rate 74.2% -59.6% 20.7%
Cash Dividends 261.00
259.00
271.00
growth rate -0.8% 4.6%
Cash From OA 975.00
951.00
674.00
444.00
growth rate -2.5% -29.1% -34.1%
Sale Purchase of Stock
growth rate
FCF 708.00
486.00
486.00
217.00
growth rate -31.4% 0.0% -55.4%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 4,890.00
5,135.00
4,995.00
5,011.00
4,641.00
growth rate 5.0% -2.7% 0.3% -7.4%
Op.Income 579.00
709.00
920.00
633.00
633.00
growth rate 22.5% 29.8% -31.2% 0.0%
IBT 514.00
266.00
723.00
421.00
421.00
growth rate -48.3% 171.8% -41.8% 0.0%
Net Income 525.00
265.00
677.00
454.00
360.00
growth rate -49.5% 155.5% -32.9% -20.7%
Gross Profit 2,161.00
2,436.00
2,457.00
2,359.00
2,078.00
growth rate 12.7% 0.9% -4.0% -11.9%
R&D 344.00
387.00
329.00
315.00
315.00
growth rate 12.5% -15.0% -4.3% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (76.56)

YOY Growth Grade:

D (47.21)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 53.57 5.93 18.85
EPS / Growth 13.6% 4.36 10.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 14.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 10.1% 12.6% 12.6%
Future PE 18.85 32.51 32.51
Future EPS 11.41 14.23 14.23
Value Price
MOS %
53.15
105.4%
114.36
342.1%
114.36
342.1%
MOS Price 26.57 57.18 57.18
IRT 4.51 4.28 4.28

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.